NVS Novinky na Forexu
Novartis Q3 Profit Declines; Lifts FY26 Core Income View, Backs Sales Outlook
Swiss drug major Novartis AG (NVS, NOVN.SW) reported Tuesday sharply lower profit in its third quarter, mainly hurt by an impairment charge and higher expenses, despite growth in net sales. Further, the firm raised fiscal 2026 outlook for core operating income and confirmed sales growth view.
RTTNews
|
Před 7 h 14 min
Novartis Stock Gains On Core Operting Income, Volume Growth In Q2; Backs Outlook
Shares of Novartis AG were gaining around 3 percent in Swiss trading and around 5 percent in pre-market activity on the NYSE on Tuesday, after the Swiss pharmaceutical major reported higher core operating income in its second quarter with growth in net sales and volume. Quarterly net profit, meanwhile, declined from last year, and the firm maintained fiscal 2026 outlook.
RTTNews
|
Před 98 dny
Novartis Q4 Core EPS Beats Market, Hikes Dividend; Sees Growth In FY25; Stock Up
Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain related to Sandoz Group AG spin-off. However, earnings from continuing operations grew from last year, and core earnings beat market estimates along with top line. Further, the company issued positive outlook for fiscal 2025 and lifted its dividend.
RTTNews
|
Před 634 dny
Novartis Lifts FY24 Outlook After Q3 Beats Market; But Stock Down
Swiss drug major Novartis AG on Tuesday raised its core operating income and sales guidance for fiscal 2024 after reporting significantly higher profit in its third quarter, driven by sales growth in key drugs. The third-quarter core earnings and topline beat market estimates. Meanwhile, the shares were losing around 3 percent in the Swiss trading as well as in early morning trading on the NYSE.
RTTNews
|
Před 728 dny
Novartis Reports Positive Results From Phase III ASC4FIRST Trial; Meets Both Primary Endpoints
Novartis AG (NVS) reported Friday positive results from the pivotal Phase III ASC4FIRST trial, which met both primary endpoints with clinically meaningful and statistically significant results.
RTTNews
|
Před 879 dny
Novartis Q1 Profit Tops Market, Lifts FY24 View, Proposes New Chair; Stock Up
Novartis AG's shares were gaining more than 4 percent in Switzerland and more than 5 percent in pre-market activity on the NYSE after the Swiss drug major reported Tuesday higher first-quarter profit, above market estimates, with strong sales growth. The company also raised its fiscal 2024 outlook for growth in sales and core operating income.
RTTNews
|
Před 917 dny
Novartis Stock Down As Q4 Core EPS Miss Estimates; Sees Growth In FY24
Shares of Novartis AG were losing more than 4 percent in the morning trading on the Switzerland exchange as well as in pre-market activity on the NYSE after the Swiss drug major's core earnings in the fourth quarter missed market estimates. On a reported basis, net profit surged on hefty income from discontinued operations related to Sandoz Group AG spin-off, as well as higher sales.
RTTNews
|
Před 1000 dny
Novartis Recalls Sandimmune Oral Solution
Swiss drug major Novartis AG is recalling two lots of its Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL at the consumer level in the US, the U.S. Food and Drug Administration said. The recall was initiated after crystal formation was observed in some bottles, which could potentially result in incorrect dosing.
RTTNews
|
Před 1064 dny
Novartis Recalls One Lot Of Sandimmune Oral Solution 100 Mg/mL
Novartis AG (NVS) announced Monday it has recalled one lot of its Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the US due to crystal formation observed in some bottles. The company added that no other Sandimmune formulations are impacted.
RTTNews
|
Před 1142 dny
Novartis Lifts FY23 View As Q2 Results Top Market, Initiates $15 Bln Buyback; Stock Up
Shares of Novartis AG were gaining around 4 percent in the morning trading in Switzerland as well as in pre-market activity on the NYSE after the drug major raised its fiscal 2023 outlook on Tuesday after reporting higher second-quarter results. Core earnings and top line beat market estimates. Further, the company announced up to $15 billion share buyback to be completed by year-end 2025.
RTTNews
|
Před 1197 dny
